Literature DB >> 31504506

Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.

Marissa J Harmsen1,2, Caroline F C Wong1,2, Velja Mijatovic1, Arjan W Griffioen2, Freek Groenman1, Wouter J K Hehenkamp1, Judith A F Huirne1.   

Abstract

BACKGROUND: Adenomyosis commonly occurs with abnormal uterine bleeding (AUB) and is associated with subfertility and a higher miscarriage rate. Recent evidence showed abnormal vascularization in the endometrium in patients with adenomyosis, suggesting a role of angiogenesis in the pathophysiology of AUB and subfertility in adenomyosis and providing a possible treatment target. OBJECTIVE AND RATIONALE: We hypothesized that the level of abnormal vascularization and expression of angiogenic markers is increased in the ectopic and eutopic endometrium of adenomyosis patients in comparison with the endometrium of control patients. This was investigated through a search of the literature. SEARCH
METHODS: A systematic search was performed in PubMed and Embase until February 2019. Combinations of terms for angiogenesis and adenomyosis were applied as well as AUB, subfertility or anti-angiogenic therapy. The main search was limited to clinical studies carried out on premenopausal women. Original research articles focusing on markers of angiogenesis in the endometrium of patients with adenomyosis were included. Studies in which no comparison was made to control patients or which were not published in a peer-reviewed journal were excluded. A second search was performed to explore the therapeutic potential of targeting angiogenesis in adenomyosis. This search also included preclinical studies. OUTCOMES: A total of 20 articles out of 1669 hits met our selection criteria. The mean vascular density (MVD) was studied by quantification of CD31, CD34, von Willebrand Factor (vWF) or factor-VIII-antibody-stained microvessels in seven studies. All these studies reported a significantly increased MVD in ectopic endometrium, and out of the six articles that took it into account, four studies reported a significantly increased MVD in eutopic endometrium compared with control endometrium. Five articles showed a significantly higher vascular endothelial growth factor expression in ectopic endometrium and three articles in eutopic endometrium compared with control endometrium. The vascular and pro-angiogenic markers α-smooth muscle actin, endoglin, S100A13, vimentin, matrix metalloproteinases (MMPs), nuclear factor (NF)-kB, tissue factor (TF), DJ-1, phosphorylated mammalian target of rapamycin, activin A, folli- and myostatin, CD41, SLIT, roundabout 1 (ROBO1), cyclooxygenase-2, lysophosphatidic acid (LPA) 1,4-5, phospho signal transducer and activator of transcription 3 (pSTAT3), interleukin (IL)-6, IL-22 and transforming growth factor-β1 were increased in ectopic endometrium, and the markers S100A13, MMP-2 and -9, TF, follistatin, myostatin, ROBO1, LPA1 and 4-5, pSTAT3, IL-6 and IL-22 were increased in eutopic endometrium, compared with control endometrium. The anti-angiogenic markers E-cadherin, eukaryotic translation initiation factor 3 subunit and gene associated with retinoic-interferon-induced mortality 19 were decreased in ectopic endometrium and IL-10 in eutopic endometrium, compared with control endometrium. The staining level of vWF and two pro-angiogenic markers (NF-κB nuclear p65 and TF) correlated with AUB in patients with adenomyosis. We found no studies that investigated the possible relationship between markers of angiogenesis and subfertility in adenomyosis patients. Nine articles reported on direct or indirect targeting of angiogenesis in adenomyosis-either by testing hormonal therapy or herbal compounds in clinical studies or by testing angiogenesis inhibitors in preclinical studies. However, there are no clinical studies on the effectiveness of such therapy for adenomyosis-related AUB or subfertility. WIDER IMPLICATIONS: The results are in agreement with our hypothesis that increased angiogenesis is present in the endometrium of patients with adenomyosis compared with the endometrium of control patients. It is likely that increased angiogenesis leads to fragile and more permeable vessels resulting in adenomyosis-related AUB and possibly subfertility. While this association has not sufficiently been studied yet, our results encourage future studies to investigate the exact role of angiogenesis in the etiology of adenomyosis and related AUB or subfertility in women with adenomyosis in order to design curative or preventive therapeutic strategies.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.

Entities:  

Keywords:  abnormal uterine bleeding; adenomyosis; angiogenesis; anti-angiogenic therapy; endometriosis; subfertility

Mesh:

Substances:

Year:  2019        PMID: 31504506      PMCID: PMC6737562          DOI: 10.1093/humupd/dmz024

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  160 in total

1.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

Review 2.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

3.  Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle.

Authors:  B Möller; C Rasmussen; B Lindblom; M Olovsson
Journal:  Mol Hum Reprod       Date:  2001-01       Impact factor: 4.025

4.  Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis.

Authors:  H Ota; S Igarashi; M Sasaki; T Tanaka
Journal:  Hum Reprod       Date:  2001-03       Impact factor: 6.918

5.  Molecular basis for treating endometriosis with aromatase inhibitors.

Authors:  S E Bulun; K M Zeitoun; K Takayama; H Sasano
Journal:  Hum Reprod Update       Date:  2000 Sep-Oct       Impact factor: 15.610

6.  Smooth muscle alpha actin and myosin heavy chain expression in the vascular smooth muscle cells surrounding human endometrial arterioles.

Authors:  K M Abberton; D L Healy; P A Rogers
Journal:  Hum Reprod       Date:  1999-12       Impact factor: 6.918

Review 7.  Regulation of vascular endothelial growth factor expression by estrogens and progestins.

Authors:  S M Hyder; J C Huang; Z Nawaz; H Boettger-Tong; S Mäkelä; C Chiappetta; G M Stancel
Journal:  Environ Health Perspect       Date:  2000-10       Impact factor: 9.031

8.  Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model.

Authors:  J Fang; Y Shing; D Wiederschain; L Yan; C Butterfield; G Jackson; J Harper; G Tamvakopoulos; M A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

9.  Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12.

Authors:  L Yao; C Sgadari; K Furuke; E T Bloom; J Teruya-Feldstein; G Tosato
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

10.  Increased microvessel density in adenomyosis uteri.

Authors:  M Schindl; P Birner; A Obermair; L Kiesel; R Wenzl
Journal:  Fertil Steril       Date:  2001-01       Impact factor: 7.329

View more
  16 in total

1.  Adenomyosis: Mechanisms and Pathogenesis.

Authors:  Junyu Zhai; Silvia Vannuccini; Felice Petraglia; Linda C Giudice
Journal:  Semin Reprod Med       Date:  2020-10-08       Impact factor: 1.303

Review 2.  Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Sci       Date:  2022-07-15       Impact factor: 2.924

3.  Decreased Glycolysis at Menstruation is Associated with Increased Menstrual Blood Loss.

Authors:  Chenyu Mao; Xishi Liu; Sun-Wei Guo
Journal:  Reprod Sci       Date:  2022-08-30       Impact factor: 2.924

4.  Transcriptome analysis of eutopic endometrial stromal cells in women with adenomyosis by RNA-sequencing.

Authors:  Lin Gan; Yongrong Li; Yan Chen; Meihua Huang; Jian Cao; Meiling Cao; Zhihui Wang; Guiping Wan; Tao Gui
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  Contrast-Enhanced Ultrasound Imaging of Uterine Disorders: A Systematic Review.

Authors:  Barbara Stoelinga; Lynda Juffermans; Anniek Dooper; Marleen de Lange; Wouter Hehenkamp; Thierry Van den Bosch; Judith Huirne
Journal:  Ultrason Imaging       Date:  2021-05-26       Impact factor: 1.578

6.  Network Pharmacology-Based Prediction of Active Ingredients and Potential Targets of ShengDiHuang Decoction for Treatment of Dysfunctional Uterine Bleeding.

Authors:  Hui Yang; Yu Fan; Jiangxue Cheng; Junbo Zou; Xiaofei Zhang; Yajun Shi; Dongyan Guo
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-11       Impact factor: 2.629

7.  Possible involvement of neuropeptide and neurotransmitter receptors in Adenomyosis.

Authors:  Xiaofang Xu; Xianjun Cai; Sun-Wei Guo; Xishi Liu
Journal:  Reprod Biol Endocrinol       Date:  2021-02-19       Impact factor: 5.211

8.  ITRAQ-based proteomics analysis of tanshinone IIA on human ectopic endometrial stromal cells of adenomyosis.

Authors:  Yong Luo; Zeng-Ming Li; Li-Ping Li; Yang Zou; Xiao-Yun Xu; Zi-Yu Zhang; Fa-Ying Liu; Yan Xiong; Lei Wan
Journal:  Arch Gynecol Obstet       Date:  2021-01-20       Impact factor: 2.344

Review 9.  Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What Is Known So Far.

Authors:  Christina Anna Stratopoulou; Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Reprod Sci       Date:  2020-10-22       Impact factor: 3.060

10.  Gehua Jiecheng Decoction Inhibits Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice by Improving Tumor Immunosuppression Microenvironment.

Authors:  Changpei Cheng; Qiyang Shou; Jiali Lang; Lu Jin; Xia Liu; Dongxin Tang; Zhu Yang; Huiying Fu
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.